Christoph e A Hartmann
Executive Country Medical Director, Uk & Ireland @MSD
Signup · Get unlimited contacts
WORK HISTORY
Executive Country Medical Director, Uk & Ireland @MSD
IE
Head of Medical Affairs UK & Ireland Team of approx 100 Therapy area responsibilities:Vaccines, Oncology, Specialty & General MedicineEnd to end life cycle responsibilities from early phase to LOE in close collaboration with clinical development, market access, commercial, etc.Chair of:Country Medical Governance Board - management of regulatory, quality, PV, clin ops, quality & crisis mattersCountry Data Council - accountable for governance of local data generation UK & Ireland Medical Leadership TeamMember of:Medical Steering Group - Association of British Pharmaceutical Industry (ABPI)Compliance Network - Prescription Medicines Code of Practice Authority (PMCPA)Extended Country Leadership team - members include early and late phase pharma arms, manufacturing, animal healthEMEAC MA Leadership team - Europe, Mid East, Africa, Canada
EDUCATION
Duke Corporate Education
Business Leadership Program, Business Administration and Management, with a focus on executive leadership and finance
North West Thames Foundation School
Foundation doctor
UCL
BSc (Hons), Neurobiology and Neurosciences
Faculty of Pharmaceutical Medicine
Diploma in Pharmaceutical Medicine
Imperial College London
MBBS, Medicine
Royal College of Surgeons
MRCS - Membership of the Royal College of Surgeon’
London School of Surgery
Core Surgery
Harvard Medical School
Clerkship in Plastic Surgery
ABOUT CHRISTOPH E A HARTMANN
Experienced pharmaceutical physician with expertise in go-to-market and medical affairs strategy, building effective teams and change management, driving performance through clear strategy, communication and culture, with an external focus, combining healthcare and business needs for best patient outcomes.Expertise in a wide range of therapy areas including Oncology, Specialty & Primary Care, Vaccines, at all stages of life cycle management (clinical trial to loss of exclusivity setting). Wealth of launch experience (20+) through end-to-end strategic execution with innovative approaches in regulatory strategy (early access, ILAP, IRP, ORBIS); market access strategy (30+ HTAs); external engagement & insight generation strategy; innovative collaborations with policy, healthcare and patient group partners; as well as sound evidence generation strategy in real world and clinical trail settings. Successfully handled a wide range of complex governance and crisis management both in clinical trial and post-market authorisation settings.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.